Floatz logo

9-valent human papillomavirus recombinant vaccine

Human Papilloma Virus

University Health Network, TorontovaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Human Papilloma Virus cohort.

Asset / SponsorPhaseRating
Gardasil 9 Vaccine
Eunice Dube
Phase 4BBB
Recombinant Nonavalent Human Papillomavirus Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 3BB
HUMAN PAPILLOMAVIRUS SEROTYPE 58 WHOLE
Beijing Health Guard Biotechnology, Inc
Phase 3BB
Hepatitis B Virus Vaccine
Eunice Dube
Phase 4BB
FLUOROURACILUM
AIDS Malignancy Consortium
Phase 3BB

View all 16 →

Same molecule, other indications

9-valent human papillomavirus recombinant vaccine is also rated in:

anal canal carcinoma in situDormant
BB
Indicative ·
66 / 100
View asset →
anogenital human papillomavirus infectionDormant
B
Indicative ·
60 / 100
View asset →
penile cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →